Ipilimumab trials for Non-Small-Cell Lung Cancer

All Ipilimumab trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Ipilimumab for Non-Small-Cell Lung Cancer

• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab
  NCT04933903 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
  NCT06364917 · Phase: Phase 2 · Ages: 18 Years to 89 Years · Sex: All (male and female) · 1 location
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations

Common questions

How many trials study Ipilimumab for Non-Small-Cell Lung Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.